Enanta Expects $194.5 Million Plus Royalties To Fund Operations Into Fiscal 2029

A manufacturing delay pushed the eczema-drug testing application to the second quarter of 2027.

Share
Enanta Expects $194.5 Million Plus Royalties To Fund Operations Into Fiscal 2029

Enanta Pharmaceuticals, which is testing drugs for respiratory syncytial virus and inflammatory diseases, expects its $194.5 million in cash and securities plus retained royalties to fund operations into fiscal 2029, according to Monday's SEC filing. Its earnings release also moved the target for an eczema-drug testing application to the second quarter of 2027 because of a manufacturing delay.

Royalties Fund The Development Bill

Enanta held the $194.5 million at September 30, 2026. Its funding forecast covers anticipated spending on its existing business and development programs.

The company discovered glecaprevir, part of AbbVie's hepatitis C treatment sold as MAVYRET in the United States and MAVIRET elsewhere. Those sales generate Enanta's royalties, but Enanta pays 54.5% of royalties to Canadian pension plan OMERS under a $200 million royalty sale treated as debt for accounting purposes. Payments run through June 30, 2032, subject to a cap of 1.42 times the purchase price; Enanta then retains all royalty cash.

Fourth-quarter revenue fell to $12.9 million from $15.1 million a year earlier. Annual revenue declined to $63 million from $65.3 million. Enanta attributed both declines to lower MAVYRET/MAVIRET sales.

Quarterly research spending rose to $26.1 million from $23.8 million, which Enanta attributed to its pediatric and high-risk adult zelicapavir trials. Annual research spending fell to $88.5 million from $106.7 million, primarily because of the timing of RSV trial expenses.

The quarterly net loss widened to $23.7 million from $18.7 million, yet loss per share narrowed to $0.81 from $0.87. Average shares outstanding rose to 29.1 million from 21.4 million. For the full year, the loss narrowed to $68.2 million from $81.9 million, or $2.35 versus $3.84 per share.

Eczema Delay, RSV Readouts Ahead

Enanta has completed preparatory work for the EDP-903 application, but a manufacturing delay moved its human-testing application target to the second quarter of 2027. The once-daily oral drug is being developed for atopic dermatitis and other diseases treated with dupilumab.

President and CEO Jay R. Luly said, "We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026". Enanta now plans to report early-stage results in the first quarter of 2027. EDP-978 targets chronic urticaria and potentially other diseases involving mast cells.

Pediatric enrollment for zelicapavir is complete, with results expected in the first quarter of 2027. Enrollment continues in its high-risk adult study, which includes people aged 75 or older and patients with chronic obstructive pulmonary disease or congestive heart failure. Enanta expects results from the mid-stage portion during 2027.

Enanta also selected EPS-5336 for development against mast cell-driven diseases, including migraine. It targets an application to begin human testing in the fourth quarter of 2027.

A September resource review led Enanta to cut approximately one-third of its workforce. The company said the cuts were intended to improve efficiency and financial flexibility while concentrating resources on priority programs.

In October, Enanta announced that Luly would retire by February 1, 2027, after 23 years with the company. The board is considering internal and external successors, and Luly is expected to remain a strategic advisor for the rest of 2027. Enanta also appointed Tara L. Kieffer, previously its chief product strategy officer, to the new chief operating officer role.

Enanta's patent dispute with Pfizer remains another business issue. In October, the European Union's Unified Patent Court ruled the patent at issue invalid and rejected Enanta's infringement action concerning Paxlovid. A separate European Patent Office opposition proceeding has a hearing scheduled for April 2027.

Enanta plans to release its fiscal first-quarter 2027 results on February 8, 2027, with pediatric RSV and early-stage EDP-978 data expected that quarter.

Sources

More on Enanta Pharmaceuticals

All Enanta Pharmaceuticals (ENTA) coverage →